UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Position in CRISPR Therapeutics AG $CRSP

Key Points

• UBS Asset Management significantly increased its holdings in CRISPR Therapeutics AG by 182.9%, acquiring an additional 1,262,560 shares, bringing their total ownership to approximately 2.26% of the company.
• CRISPR Therapeutics reported an earnings per share (EPS) of ($1.29) for the last quarter, exceeding expectations, despite the total revenue of $0.89 million falling short of analyst predictions.
• Multiple analysts have raised their price targets on CRISPR shares, with Piper Sandler maintaining an "overweight" rating and setting a target at $105.00, indicating strong investor interest and confidence in the stock.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 182.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,952,751 shares of the company's stock after purchasing an additional 1,262,560 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 2.26% of CRISPR Therapeutics worth $66,452,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CRSP. SVB Wealth LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at approximately $25,000. Wood Tarver Financial Group LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth $30,000. Costello Asset Management INC acquired a new position in CRISPR Therapeutics during the 1st quarter worth $27,000. Ameriflex Group Inc. acquired a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $36,000. Finally, Quantbot Technologies LP lifted its stake in shares of CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock valued at $45,000 after purchasing an additional 978 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George bought 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The shares were bought at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded up $3.35 during trading on Tuesday, hitting $61.19. The company's stock had a trading volume of 4,619,759 shares, compared to its average volume of 1,713,418. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The stock has a market cap of $5.57 billion, a price-to-earnings ratio of -11.27 and a beta of 1.81. The stock has a 50-day moving average price of $56.99 and a two-hundred day moving average price of $45.95.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same quarter in the previous year, the business earned ($1.49) earnings per share. CRISPR Therapeutics's revenue for the quarter was up 72.5% on a year-over-year basis. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on CRSP. Chardan Capital reaffirmed a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Piper Sandler reiterated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Bank of America decreased their price objective on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Zacks Research upgraded CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Finally, Royal Bank Of Canada raised their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research note on Tuesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $71.60.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.